Literature DB >> 31015235

Robust response to nivolumab in patient with renal cell carcinoma inferior vena cava tumour thrombus.

Joel Berends1, Eric Gourley1, Dharam Kaushik1.   

Abstract

A 47-year-old previously healthy man presented with acute moderate flank pain. Evaluation revealed left renal cell carcinoma, with inferior vena cava tumour thrombus invasion. Patient had no significant history or risk factors to pre-dispose him to genitourinary cancers. Surgery was deemed to not be appropriate due to distant metastases, but patient received targeted molecular therapy and immunotherapy with striking regression of the thrombus. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; immunological products and vaccines; urological surgery; urology

Mesh：

Substances：

Year:  2019        PMID： 31015235      PMCID： PMC6506063          DOI： 10.1136/bcr-2018-227030

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  21 in total

1.  Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis.

Authors:  Charles A Field; Brittney H Cotta; Juan Jimenez; Brian R Lane; Kendrick Yim; Hak J Lee; Stephen T Ryan; Zachary A Hamilton; Sunil Patel; Song Wang; Christopher J Kane; Sumi Dey; Rana R Mckay; Sabrina Noyes; Frederick E Millard; Brian I Rini; Steven C Campbell; Ithaar H Derweesh
Journal:  Clin Genitourin Cancer       Date:  2019-01-30       Impact factor: 2.872

2.  Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study.

Authors:  Tomoaki Terakawa; Ahmed A Hussein; Yukari Bando; Khurshid A Guru; Junya Furukawa; Katsumi Shigemura; Kenichi Harada; Nobuyuki Hinata; Yuzou Nakano; Masato Fujisawa
Journal:  Anticancer Drugs       Date:  2018-07       Impact factor: 2.248

Review 3.  Role of embolization in the treatment of renal masses.

Authors:  David Li; Bradley B Pua; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

Review 4.  Nivolumab in renal cell carcinoma: latest evidence and clinical potential.

Authors:  Camille Mazza; Bernard Escudier; Laurence Albiges
Journal:  Ther Adv Med Oncol       Date:  2016-12-11       Impact factor: 8.168

5.  Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.

Authors:  Hironori Fukuda; Tsunenori Kondo; Toshio Takagi; Jumpei Iizuka; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2017-04-01       Impact factor: 3.402

6.  Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?

Authors:  Pierre Bigot; Tarek Fardoun; Jean Christophe Bernhard; Evanguelos Xylinas; Julien Berger; Morgan Rouprêt; Jean-Baptiste Beauval; Samuel Lagabrielle; Souhil Lebdai; Myriam Ammi; Hervé Baumert; Bernard Escudier; Nicolas Grenier; Jean-François Hétet; Jean-Alexandre Long; Philippe Paparel; Nathalie Rioux-Leclercq; Michel Soulié; Abdel-Rahmène Azzouzi; Karim Bensalah; Jean-Jacques Patard
Journal:  World J Urol       Date:  2013-04-27       Impact factor: 4.226

7.  Updates to the Management of Kidney Cancer.

Authors:  Eric Jonasch
Journal:  J Natl Compr Canc Netw       Date:  2018-05       Impact factor: 11.908

Review 8.  International variations and trends in renal cell carcinoma incidence and mortality.

Authors:  Ariana Znaor; Joannie Lortet-Tieulent; Mathieu Laversanne; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2014-10-16       Impact factor: 20.096

9.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

10.  Role of presurgical targeted molecular therapy in renal cell carcinoma with an inferior vena cava tumor thrombus.

Authors:  Cheng Peng; Liangyou Gu; Lei Wang; Qingbo Huang; Baojun Wang; Gang Guo; Yang Fan; Yu Gao; Xin Ma; Xu Zhang
Journal:  Onco Targets Ther       Date:  2018-04-06       Impact factor: 4.147
View more
  2 in total

1.  Comparison of PD-L1 Scores in Primary Kidney Tumors Versus Accompanying Venous Tumor Thrombi: Retrospective, Comparative, Monocentric Study in Treatment-Naive Patients.

Authors:  Mehrdad Mazdak; Rieke Ringlstetter; Pouriya Faraj Tabrizi; Meryem Akkoyun; Mathias Wolters; Jessica Schmitz; Jan Hinrich Bräsen; Inga Peters; Markus Antonius Kuczyk; Hossein Tezval
Journal:  Adv Ther       Date:  2021-05-21       Impact factor: 3.845

2.  Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing.

Authors:  Yue Shi; Qi Zhang; Hai Bi; Min Lu; Yezhen Tan; Daojia Zou; Liyuan Ge; Zhigang Chen; Cheng Liu; Weimin Ci; Lulin Ma
Journal:  Genome Biol       Date:  2022-03-31       Impact factor: 13.583
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.